BioLineRx (BLRX) Asset Utilization Ratio (2024 - 2026)
BioLineRx (BLRX) posted quarterly Asset Utilization Ratio of 0.03 for Q4 2025, down 95.37% year-over-year from 0.63 in Q4 2024, and down 90.46% quarter-over-quarter from 0.31 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Asset Utilization Ratio (2024 - 2026) Analysis & Trends
BioLineRx's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.03 for Q4 2025.
- In Q4 2025, Asset Utilization Ratio fell 95.37% year-over-year to 0.03; the TTM figure through Dec 2025 stood at 0.03 (down 95.37% YoY), while the FY2025 annual figure was 0.03, down 94.75% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.03, down from 0.31 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.63 in Q4 2024, with the low at 0.03 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.13 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 0.54 |
| 10 | BioLineRx | 6.68 Bn | 6.68 Bn | 235,000.00 | 0.04 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.04 |
| Mar 31, 2026 | 0.04 |
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.31 |
| Jun 30, 2025 | 0.40 |
| Mar 31, 2025 | 0.54 |
| Dec 31, 2024 | 0.63 |
| Sep 30, 2024 | 0.29 |